APA

Islamagic E., Hasic A., Kurtovic S., Suljovic Hadzimesic E., Mehinovic L., Kozaric M. & Kurtovic-Kozaric A. (20171108). The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. : Clinical lymphoma, myeloma & leukemia.

Chicago

Islamagic Erna, Hasic Azra, Kurtovic Sabira, Suljovic Hadzimesic Emina, Mehinovic Lejla, Kozaric Mirza and Kurtovic-Kozaric Amina. 20171108. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. : Clinical lymphoma, myeloma & leukemia.

Harvard

Islamagic E., Hasic A., Kurtovic S., Suljovic Hadzimesic E., Mehinovic L., Kozaric M. and Kurtovic-Kozaric A. (20171108). The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. : Clinical lymphoma, myeloma & leukemia.

MLA

Islamagic Erna, Hasic Azra, Kurtovic Sabira, Suljovic Hadzimesic Emina, Mehinovic Lejla, Kozaric Mirza and Kurtovic-Kozaric Amina. The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. : Clinical lymphoma, myeloma & leukemia. 20171108.